Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
BioCryst Pharmaceuticals gains Japan pediatric approval as ORLADEYO revenue momentum builds
Japan expands ORLADEYO to younger children as BioCryst Pharmaceuticals builds its growing global hereditary angioedema franchise.
Zymeworks gets $250m boost after Ziihera wins major first-line cancer approval
FDA expands Ziihera into first-line HER2-positive gastroesophageal cancer, unlocking $250 million for Zymeworks. See why the approval matters.
Moderna proposes $2bn zero-coupon notes as oncology success reshapes capital strategy
Moderna plans a $2 billion private placement of zero-regular-interest convertible notes due 2032, with a possible additional $300 million and capped-call protection designed to reduce dilution as the company prepares for increased oncology investment.
Jazz Pharmaceuticals raises $1.1bn at 1.875% while repurchasing $225m of stock
Jazz Pharmaceuticals has priced $1.1 billion of 1.875% exchangeable notes due 2032, generating about $1.08 billion of net proceeds while concurrently repurchasing $225 million of shares.
Mesoblast revenue jumps sevenfold to $120m as Ryoncil turns cell therapy into a commercial business
Mesoblast generated $120.3 million of FY26 revenue, including $115.2 million from Ryoncil, while narrowing its loss 44% and advancing adult GVHD, Duchenne, back pain and heart-failure programmes.
Rhythm Pharmaceuticals wins Japan approval for IMCIVREE as rare obesity growth story expands
Japan approves IMCIVREE for acquired hypothalamic obesity as Rhythm Pharmaceuticals expands globally. See what the launch could mean for growth.
Erasca’s $6.2bn valuation faces bigger test as ERAS-0015 heads toward three pivotal trials
ERAS-0015 wins FDA Fast Track status as Erasca deploys nearly $1bn behind three planned pivotal cancer trials after an early 57% response signal.
CAPR jumps 15% as FDA gives deramiocel three more months to rescue Duchenne approval bid
CAPR jumps as FDA extends deramiocel review to November 22, giving Capricor more time to support its Duchenne upper limb approval case.
Revolution Medicines wins FDA approval for Rasonque after 60% reduction in death risk
The FDA has approved Revolution Medicines’ Rasonque for previously treated metastatic pancreatic adenocarcinoma after a Phase 3 trial showed median overall survival of 13.2 months versus 6.7 months with chemotherapy.
Valerio Therapeutics to buy Etherna for €30m; raises €40.25m
The €40.25 million PIPE is larger than Etherna’s €30 million enterprise value, giving Valerio capital not only for the acquisition but also for pipeline development and in-house GMP RNA manufacturing.